Pds biotech announces colorectal cancer cohort of phase 2 clinical trial with pds01adc met criteria for expansion to stage 2 following positive stage 1 results

Princeton, n.j., july 10, 2025 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced patient recruitment has been completed in stage 1 of a clinical trial of the company's pds01adc therapeutic administered systemically in combination with floxuridine (fudr) administered by hepatic artery infusion pump (haip) for patients with metastatic colorectal cancer (nct05286814), led by the national cancer institute (nci), a component of the national institutes of health (nih).
PDSB Ratings Summary
PDSB Quant Ranking